KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Gross Margin (2016 - 2025)

Historic Gross Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to 82.56%.

  • Halozyme Therapeutics' Gross Margin fell 33200.0% to 82.56% in Q4 2025 from the same period last year, while for Dec 2025 it was 83.62%, marking a year-over-year decrease of 6800.0%. This contributed to the annual value of 83.62% for FY2025, which is 6800.0% down from last year.
  • Halozyme Therapeutics' Gross Margin amounted to 82.56% in Q4 2025, which was down 33200.0% from 84.41% recorded in Q3 2025.
  • Halozyme Therapeutics' Gross Margin's 5-year high stood at 86.42% during Q1 2022, with a 5-year trough of 74.62% in Q3 2023.
  • Moreover, its 5-year median value for Gross Margin was 82.14% (2025), whereas its average is 81.15%.
  • Per our database at Business Quant, Halozyme Therapeutics' Gross Margin plummeted by -81100bps in 2023 and then surged by 86200bps in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Gross Margin stood at 78.84% in 2021, then decreased by -3bps to 76.79% in 2022, then increased by 1bps to 77.27% in 2023, then grew by 11bps to 85.89% in 2024, then dropped by -4bps to 82.56% in 2025.
  • Its Gross Margin was 82.56% in Q4 2025, compared to 84.41% in Q3 2025 and 85.77% in Q2 2025.